2026-10-25
Hinge Health, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 27,087 +1.72%
S&P 7,401 +0.65%
GOLD $4,073 −1.00%
BTC $75,828 −0.15%
VIX 24.55 −12.88%
latest tape · as of 20:03 UTC
The Screen · Healthcare · Health Information Services
Hinge Health, Inc.
HNGE · the NYSE · USD · Market cap $9.8B · 1,437 employees
Hinge Health, Inc.
Not yet scored115.98 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price115.98 USD at the 5 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 5 Nov 2026
- Our regime readAccumulation, as of 5 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans slightly to calls (put/call 0.73)
- Last reviewed5 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $81.00 to $118.81, base estimate $103.31 (screen dated 2026-11-05).
- Trend Accumulation
- Insiders insiders sold, $4,921,578, latest filing 2026-10-12
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.73, read 2026-11-05
- Ethical screen not yet scored
Price115.98 USD
Fair value103.31
Ethical score70.0/100
Value readOvervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-09-01Read Accumulation90.50+28.2% to today ✓Markup gives way to Accumulation after a 21% rise in 4 weeks
2026-08-01Read Markup74.71+55.2% to today ✓Accumulation gives way to Markup after a 14% rise in 4 weeks
2026-07-02Read Accumulation65.34+77.5% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
Hinge Health, Inc. holds its Accumulation at $115.98. The statistical read favours the buyers, held for 9 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the buyers, held for 9 days |
| Price at the screen | $115.98 |
| Valuation | 32.76 trailing · 37.13 forward price to earnings |
| Values screen | Not scored · score 70.0 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 1.08% | Below 33% | Interest-bearing debt is just 1.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 15.20% | Below 33% | Cash held in interest-bearing accounts and securities is 15.2% of assets, under the one-third limit. | Pass |
| Receivables | 34.78% | Below 49% | Money owed to the company is 34.8% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Hinge Health, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Hinge Health, clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $103.31 fair value estimate, 52.40% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 12.3% above the base estimate.
Third-party analyst targets: 16 covering, consensus Buy. The average target sits +16% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $103.31, with a range of $81.00 to $118.81, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsDigital rehab platform priced well above its worth
Every time a worker strains their back on the job or an athlete needs post op rehab, the old system of clinics and physios still dominates. Hinge Health wants to automate that care through an app led platform, and the revenue line is racing ahead at 47 percent. Yet the shares trade at 87 dollars against our fair value of 77 dollars, a margin that already sits in negative territory, and the business is still posting a 79 percent negative profit margin with return on equity at minus 136 percent.
We pass for straightforward valuation reasons. Forward earnings sit on a 25.6 times multiple while the company remains deeply unprofitable, and analyst targets cluster around 80 dollars, offering little cushion. Strong revenue growth alone does not justify stretching the price when cash is still flowing out at scale and the moat remains unproven in a crowded health tech space.
Risks centre on execution and cash burn. Sustained losses at this level can quickly erode investor patience if growth slows or reimbursement contracts prove harder to win than hoped. The ethical screen is clear, yet the numbers still show a business priced for perfection it has not yet delivered. Analysis, not advice.
| Forward P/E | 37.1xcheap for a company growing this fast |
| Trailing P/E | 32.8xa premium valuation |
| EPS, trailing | 3.69 |
| EPS, forward | 3.26 |
| Revenue growth | +52.4%growing very fast |
| Profit margin | 21.0%healthy profit margins |
| Return on equity | 47.6%an exceptional return on shareholder capital |
| FCF yield | 3.22% |
| Debt to equity | 0.11minimal debt: a conservative balance sheet |
| Current ratio | 1.04adequate liquidity, worth monitoring |
| Short interest, float | 0.10% |
| 52-week range | 30.08 - 124.93 |
| Market cap | $9.8B |
| Employees | 1,437 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeHNGE trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-02
Accumulation $114.32
+0.0% Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 71% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Accumulation $114.32
+2.5% Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 71% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Accumulation $111.52
+0.0% Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 71% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Accumulation $111.52
+0.0% Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 71% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Accumulation $111.52
+3.7% Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 71% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28
Accumulation $107.51
+0.0% Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 71% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27
Accumulation $107.51
+0.0% Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 71% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26
Accumulation $107.51
+0.0% Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 71% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Accumulation $107.51
+4.5% Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 55% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71. Insiders have been net sellers over the past quarter.
2026-10-14
Accumulation $102.90
+5.1% Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (15 analysts) rates it buy, with a mean price target of $71.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Apple, Super Micro, AMD, Palantir Step Up To Earnings Plate After Tech Sell-Off Yahoo Finance · 7d ago
- Reasons to Hold Hinge Health Stock in Your Portfolio for Now Yahoo Finance · 8d ago
- Hinge Health (HNGE) Stock Sees Modest Fair Value Lift As Analysts Raise Targets Yahoo Finance · 10d ago
- BofA names top application software stocks heading into Q3 earnings Yahoo Finance · 11d ago
- Hinge Health to announce third quarter 2026 financial results on November 2, 2026 Yahoo Finance · 5 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
TXG10x Genomics, Inc.
TEMTempus AI, Inc.
BTSGBrightSpring Health Services Inc
WAYWaystar Holding Corp.
DOCSDoximity, Inc.
HTFLHeartflow, Inc.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-12 | Budge James | CFO | S - Sale | 47,720 | $4,921,578 |
| 2026-10-12 | Mecklenburg Gabriel M.I. | Exec. Chairman & Co-Founder | S - Sale+OE | 200,000 | $20,626,371 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $54.74 | +13.4% | · | $1,134 | +13.4% |
| 2 months | $35.41 | +75.3% | · | $1,753 | +75.3% |
| 3 months | $44.46 | +39.6% | · | $1,396 | +39.6% |
| 6 months | $49.79 | +24.7% | · | $1,247 | +24.7% |
| 1 year | $36.59 | +69.7% | · | $1,697 | +69.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever HNGE does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.